Listing contains 13 trial(s)
Skin Cancer, Melanoma
Lab
A Study Of Potential Markers of Tumor Progression In Atypical Nevi Study Number: 94-39 |
University of Pittsburgh Cancer Institute: Blood Serum Lymphocyte, and Tumor Tissue Banking For Melanoma Patients Study Number: 96-099 |
Phase I
Phase I Evaluation of alpha-type-1DC-based and cDC-based Intralymphatic Vaccines in Patients with Metastatic Melanoma Study Number: 03-118 |
Phase II
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients with Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor (ECOG #E2602) Study Number: 03-111 |
A Phase II Study of the Anti-Ganglioside GD3 Mouse/Human Chimeric Antibody KW2871 Combined with High Dose Interferon-a2b in Patients with Metastatic Cutaneous Melanoma Study Number: 07-023 |
A Phase II Trial of Dasatinib in Advanced Sarcoma Study Number: 08-006 |
A Phase II Trial of Dasatinib in Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Solar Melanomas Study Number: 09-041 |
Phase III
A Phase III Study of Four Weeks of High Dose IFN Alpha 2b in Stage IIA Melanoma Study Number: 99-006 |
A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma Study Number: 08-136 |
Pilot
Safety and Immunogencity Pilot Study of Immunization with Multi-Epitope Peptide Vaccine Containing MART-1,gp100, and Tyrosinase Peptides in Combination with GMCSF-in-Adjuvant or CpG Oligonucleotide (PF3512676) or Both for Recurrent Inoperable Stage III or Stage IV Melanoma Study Number: 04-173 |
Sentinel Node and Non-Sentinel Lymph Nodes (SLN and non-SLN) Procurement for Molecular Profiling Analysis Study Number: 07-133 |
Pilot Analysis of the Effects of IFN ±2b upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients with and without Tumor-Involved Sentinel Lymph Nodes Study Number: 08-067 |
Neoadjuvant Anti-CTLA4 Blockade with Ipilimumab in Patients with AJCC Stage IIIB-C (Tx,1-4, N1b,2b, 2c, 3, M0) Melanoma: Immunogenicity And Biomarker Analysis Study Number: 08-144 |
